Precision Medicine Quarterly

Exact Sciences to Acquire Thrive Earlier Detection, Becoming a Leader in Blood-Based, Multi-Cancer Screening

2021-01-27T06:35:21-05:00October 27th, 2020|

Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. (“Thrive”), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion. The transaction was unanimously approved [...]

Sema4 Announces Collaboration with Janssen on Optimizing Oncology Clinical Trials

2021-01-27T06:26:55-05:00October 1st, 2020|

Sema4, a patient-centered health intelligence company, today announced that it has entered into a research agreement with Janssen Research & Development, LLC (Janssen) to optimize oncology clinical trials. Together, Sema4 and Janssen will utilize genomic testing and advanced data analytics to more efficiently and accurately identify patients diagnosed with cancer who may be candidates for [...]

Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics

2021-01-27T06:16:12-05:00October 1st, 2020|

Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeutics, today announced a broad, multi-year collaboration aimed at accelerating the discovery and development of innovative therapeutics across a range of up to 20 diseases. The collaboration is expected to play an important role in allowing Ionis to [...]

Cancer Genomic Screening Program LC-SCRUM-Asia Adopts Latest Thermo Fisher Scientific NGS Solutions

2021-01-27T05:23:13-05:00October 1st, 2020|

LC-SCRUM-Asia, a leading cancer genomic screening program, has selected Thermo Fisher Scientific’s Ion Torrent Genexus System* and Oncomine Precision Assay*, a pan-cancer panel, to advance precision medicine in Asia. The next-generation sequencing (NGS) solutions will be used in two prospective, observational projects to support the development of future therapeutics and diagnostics for non-small cell lung [...]

Go to Top